Effects of combined oral contraceptives on the clinical and biochemical parameters of hyperandrogenism in patients with polycystic ovary syndrome: a systematic review and meta-analysis

References

• Azziz R, Woods KS, Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89:2745–2749.
   PubMed Web of Science ®Google Scholar
• Asunción M, Calvo RM, San Millán JL, et al. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain 1. J Clin Endocrinol Metab. 2000;85:2434–2438.
   PubMed Web of Science ®Google Scholar
• Halperin IJ, Kumar SS, Stroup DF, et al. The association between the combined oral contraceptive pill and insulin resistance, dysglycemia and dyslipidemia in women with polycystic ovary syndrome: a systematic review and meta-analysis of observational studies. Hum Reprod. 2010;26:191–201.
   PubMed Web of Science ®Google Scholar
• Tehrani FR, Simbar M, Tohidi M, et al. The prevalence of polycystic ovary syndrome in a community sample of Iranian population: Iranian PCOS prevalence study. Reprod Biol Endocrinol. 2011;9:1.
   Web of Science ®Google Scholar
• Helvaci N, Yildiz BO. Oral contraceptives in polycystic ovary syndrome. Minerva Endocrinol. 2014;39:175–187.
   PubMed Web of Science ®Google Scholar
• Rojanasakul A, Sirimongkolkasem R, Piromsawasdi S, et al. Effects of combined ethinylestradiol and desogestrel on hormone profiles and sex hormone binding globulin in women with polycystic ovarian disease. Contraception. 1987;36:633–640.
   PubMed Web of Science ®Google Scholar
• Carlstrom K, Karlsson R, Schoultz BV. Diurnal rhythm and effects of oral contraceptives on serum dehydroepiandrosterone sulfate (DHEAS) are related to alterations in serum albumin rather than to changes in adrenocortical steroid secretion. Scand J Clin Lab Invest. 2002;62:361–368.
   PubMed Web of Science ®Google Scholar
• Vrbikova J, Cibula D. Combined oral contraceptives in the treatment of polycystic ovary syndrome. Hum Reprod Update. 2005;11:277–291.
   PubMed Web of Science ®Google Scholar
• Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005;352:1223–1236.
   PubMed Web of Science ®Google Scholar
• De Leo V, Di Sabatino A, Musacchio MC, et al. Effect of oral contraceptives on markers of hyperandrogenism and SHBG in women with polycystic ovary syndrome. Contraception. 2010;82:276–280.
   PubMed Web of Science ®Google Scholar
• Guido M, Romualdi D, Giuliani M, et al. Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. J Clin Endocrinol Metab. 2004;89:2817–2823.
   PubMed Web of Science ®Google Scholar
• Palep-Singh M, Mook K, Barth J, et al. An observational study of Yasmin® in the management of women with polycystic ovary syndrome. J Fam Plann Reprod Health Care. 2004;30:163–165.
   PubMed Web of Science ®Google Scholar
• Taheripanah R, Sepahvandi M, Entezari A, et al. Evaluation of serum PSA after cyproterone compound treatment compared with oral contraceptive pill in hirsute polycystic ovary syndrome patients. Middle East Fertil Soc J. 2010;15:159–162.
   Google Scholar
• Colonna L, Pacifico V, Lello S, et al. Skin improvement with two different oestroprogestins in patients affected by acne and polycystic ovary syndrome: clinical and instrumental evaluation. J Eur Acad Dermatol Venereol. 2012;26:1364–1371.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–269.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Green S, Cochrane handbook for systematic reviews of interventions. Vol. 5. Chichester: Wiley Online Library; 2008.
   Google Scholar
• Yildizhan R, Gokce AI, Yildizhan B, et al. Comparison of the effects of chlormadinone acetate versus drospirenone containing oral contraceptives on metabolic and hormonal parameters in women with PCOS for a period of two-year follow-up. Gynecol Endocrinol. 2015;31:396–400.
   PubMed Web of Science ®Google Scholar
• Ilie IR, Marian I, Mocan T, et al. Ethinylestradiol 30μg-drospirenone and metformin: could this combination improve endothelial dysfunction in polycystic ovary syndrome?. BMC Endocr Disord. 2012;12:1.
   PubMed Web of Science ®Google Scholar
• Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol. 2010;63:e1–e37.
   PubMed Web of Science ®Google Scholar
• Yu L, Kronen RJ, Simon LE, et al. Prophylactic negative pressure wound therapy after cesarean is associated with reduced risk of surgical site infection: a systematic review and meta-analysis. Am J Obstet Gynecol. 2017;218:200–210.
   PubMed Web of Science ®Google Scholar
• Quigley J, Thompson J, Halfpenny N, et al. Critical appraisal of non-randomized controlled trials – a review of recommended and commonly used tools. Value Health. 2014;17:A203.
   Web of Science ®Google Scholar
• Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928
   PubMed Web of Science ®Google Scholar
• Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919
   PubMed Web of Science ®Google Scholar
• Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5:1.
   PubMedGoogle Scholar
• Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088–1101.
   PubMed Web of Science ®Google Scholar
• Egger M, Smith GD, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–634.
   PubMed Web of Science ®Google Scholar
• Duval S, Tweedie R. Trim and fill: a simple funnel‐plot-based method of testing and adjusting for publication bias in meta‐analysis. Biometrics. 2000;56:455–463.
   PubMed Web of Science ®Google Scholar
• Taylor S, TWeedie R, Trim and fill: a simple funnel plot based method of testing and adjusting for publication bias in meta-analyses. Fort Collins (CO): Colorado State University; 1998.
   Google Scholar
• Nader S, Riad-Gabriel MG, Saad MF. The effect of a desogestrel-containing oral contraceptive on glucose tolerance and leptin concentrations in hyperandrogenic women. J Clin Endocrinol Metab. 1997;82:3074–3077.
   PubMed Web of Science ®Google Scholar
• Morin-Papunen LC, Vauhkonen I, Koivunen RM, et al. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab. 2000;85:3161–3168.
   PubMed Web of Science ®Google Scholar
• Armstrong VL, Wiggam MI, Ennis CN, et al. Insulin action and insulin secretion in polycystic ovary syndrome treated with ethinyl oestradiol/cyproterone acetate. QJM. 2001;94:31–37.
   PubMedGoogle Scholar
• Falsetti L, Gambera A, Tisi G. Efficacy of the combination ethinyl oestradiol and cyproterone acetate on endocrine, clinical and ultrasonographic profile in polycystic ovarian syndrome. Hum Reprod. 2001;16:36–42.
   PubMed Web of Science ®Google Scholar
• Elter K, Imir G, Durmusoglu F. Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Hum Reprod. 2002;17:1729–1737.
   PubMed Web of Science ®Google Scholar
• Mastorakos G, Koliopoulos C, Creatsas G. Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives. Fertil Steril. 2002;77:919–927.
   PubMed Web of Science ®Google Scholar
• Cagnacci A, Paoletti A, Renzi A, et al. Glucose metabolism and insulin resistance in women with polycystic ovary syndrome during therapy with oral contraceptives containing cyproterone acetate or desogestrel. J Clin Endocrinol Metab. 2003;88:3621–3625.
   PubMed Web of Science ®Google Scholar
• Liqun L, Yi L, Yongyu S, et al. Effects of metformin combined with cyproterone acetate on clinical features, endocrine and metabolism of non-obese women with polycystic ovarian syndrome. J Huazhong Univ Sci Technol [Med Sci]. 2005;25:194–197.
   PubMedGoogle Scholar
• Pehlivanov B, Mitkov M. Efficacy of an oral contraceptive containing drospirenone in the treatment of women with polycystic ovary syndrome. Eur J Contracept Reprod Health Care. 2007;12:30–35.
   PubMed Web of Science ®Google Scholar
• Wu J, Zhu Y, Jiang Y, et al. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome. Gynecol Endocrinol. 2008;24:392–398.
   PubMed Web of Science ®Google Scholar
• Gregoriou O, Papadias K, Konidaris S, et al. Treatment of hirsutism with combined pill containing drospirenone. Gynecol Endocrinol. 2008;24:220–223.
   PubMed Web of Science ®Google Scholar
• Ozdemir S, Gorkemli H, Gezginc K, et al. Clinical and metabolic effects of medroxyprogesterone acetate and ethinyl estradiol plus drospirenone in women with polycystic ovary syndrome. Int J Gynaecol Obstet. 2008;103:44–49.
   PubMed Web of Science ®Google Scholar
• Gul OB, Somunkiran A, Yucel O, et al. The effect of ethinyl estradiol-cyproterone acetate treatment on homocysteine levels in women with polycystic ovary syndrome. Arch Gynecol Obstet. 2008;277:25–30.
   PubMed Web of Science ®Google Scholar
• Bilgir O, Kebapcilar L, Taner C, et al. The effect of ethinylestradiol (EE)/cyproterone acetate (CA) and EE/CA plus metformin treatment on adhesion molecules in cases with polycystic ovary syndrome (PCOS). Intern Med. 2009;48:1193–1199.
   PubMed Web of Science ®Google Scholar
• Kebapcilar L, Yuksel A, Bozkaya G, et al. Effects of an EE/CA compared with EE/CA-metformin on serum ADMA levels in women with polycystic ovary syndrome. Cent Eur J Med 2009;4:423–427.
   Google Scholar
• Mahmood M, El-Kattan EA, El-Aal HA, et al. Evaluation of the Clinical and Biochemical Effects of Medical Therapy in Women with Polycystic Ovary Syndrome. Med J Cairo Univ 2009;77:59–67.
   Google Scholar
• Sagsoz N, Orbak Z, Noyan V, et al. The effects of oral contraceptives including low-dose estrogen and drospirenone on the concentration of leptin and ghrelin in polycystic ovary syndrome. Fertil Steril. 2009;92:660–666.
   PubMed Web of Science ®Google Scholar
• Chen M-J, Yang W-S, Chen H-F, et al. Increased follistatin levels after oral contraceptive treatment in obese and non-obese women with polycystic ovary syndrome. Hum Reprod. 2010;25:779–785.
   PubMed Web of Science ®Google Scholar
• Kriplani A, Periyasamy AJ, Agarwal N, et al. Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome. Contraception. 2010;82:139–146.
   PubMed Web of Science ®Google Scholar
• Teede HJ, Meyer C, Hutchison SK, et al. Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy. Fertil Steril. 2010;93:184–191.
   PubMed Web of Science ®Google Scholar
• Panidis D, Georgopoulos NA, Piouka A, et al. The impact of oral contraceptives and metformin on anti-Müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia. Gynecol Endocrinol. 2011;27:587–592.
   PubMed Web of Science ®Google Scholar
• Naka KK, Kalantaridou SN, Bechlioulis A, et al. Effect of ethinylestradiol/cyproterone acetate on endothelial function in young non-obese women with polycystic ovary syndrome: a pilot study. Gynecol Endocrinol. 2011;27:615–621.
   PubMed Web of Science ®Google Scholar
• Karabulut A, Demirlenk S, Åževket O. Effects of ethinyl estradiol-cyproterone acetate treatment on metabolic syndrome, fat distribution and carotid intima media thickness in polycystic ovary syndrome. Gynecol Endocrinol. 2012; 28:245–248.
   PubMed Web of Science ®Google Scholar
• Bhattacharya SM, Jha A. Comparative study of the therapeutic effects of oral contraceptive pills containing desogestrel, cyproterone acetate, and drospirenone in patients with polycystic ovary syndrome. Fertil Steril. 2012;98:1053–1059.
   PubMed Web of Science ®Google Scholar
• Romualdi D, De Cicco S, Busacca M, et al. Clinical efficacy and metabolic impact of two different dosages of ethinyl-estradiol in association with drospirenone in normal-weight women with polycystic ovary syndrome: a randomized study. J Endocrinol Invest. 2013;36:636–641.
   PubMed Web of Science ®Google Scholar
• Aydin K, Cinar N, Aksoy DY, et al. Body composition in lean women with polycystic ovary syndrome: effect of ethinyl estradiol and drospirenone combination. Contraception. 2013;87:358–362.
   PubMed Web of Science ®Google Scholar
• Kahraman K, Sukur YE, Atabekoglu CS, et al. Comparison of two oral contraceptive forms containing cyproterone acetate and drospirenone in the treatment of patients with polycystic ovary syndrome: a randomized clinical trial. Arch Gynecol Obstet. 2014;290:321–328.
   PubMed Web of Science ®Google Scholar
• Macut D, Antic IBi, Nestorov J, et al. The influence of combined oral contraceptives containing drospirenone on hypothalamic-pituitary-adrenocortical axis activity and glucocorticoid receptor expression and function in women with polycystic ovary syndrome. Hormones (Athens). 2015;14:109–119.
   PubMedGoogle Scholar
• Mathur R, Levin O, Azziz R. Use of ethinylestradiol/drospirenone combination in patients with the polycystic ovary syndrome. Ther Clin Risk Manag. 2008;4:487–492.
   PubMedGoogle Scholar
• Nader S, Diamanti-Kandarakis E. Polycystic ovary syndrome, oral contraceptives and metabolic issues: new perspectives and a unifying hypothesis. Hum Reprod. 2007;22:317–322.
   PubMed Web of Science ®Google Scholar
• Wiebe RH, Morris CV. Effect of an oral contraceptive on adrenal and ovarian androgenic steroids. Obstet Gynecol. 1984;63:12–14.
   PubMed Web of Science ®Google Scholar
• Klove KL, Roy S, Lobo RA. The effect of different contraceptive treatments on the serum concentration of dehydroepiandrosterone sulfate. Contraception. 1984;29:319–324.
   PubMed Web of Science ®Google Scholar
• Wiegratz I, Jung-Hoffmann C, Kuhl H. Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins. Contraception. 1995;51:341–346.
   PubMed Web of Science ®Google Scholar
• Batukan C, Muderris II. Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism. Fertil Steril. 2006;85:436–440.
   PubMed Web of Science ®Google Scholar
• Wiegratz I, Kutschera E, Lee J, et al. Effect of four different oral contraceptives on various sex hormones and serum-binding globulins. Contraception. 2003;67:25–32.
   PubMed Web of Science ®Google Scholar
• Hohl A, Ronsoni MF, Oliveira M. Hirsutism: diagnosis and treatment. Arq Bras Endocrinol Metabol. 2014;58:97–107.
   PubMed Web of Science ®Google Scholar
• Reeves BC, Deeks JJ, Higgins JP, et al. Including non-randomized studies. In: Higgins JPT, Green. S, editors. Cochrane handbook for systematic reviews of interventions version. London: The Cochrane Collaboration; 2008.
   Google Scholar
• Zimmerman Y, Eijkemans MJC, Bennink HJTC, et al. The effect of combined oral contraception on testosterone levels in healthy women: a systematic review and meta-analysis. Hum Reprod Update. 2014;20:76–105.
   PubMed Web of Science ®Google Scholar
• Mendoza N, Simoncini T, Genazzani AD. Hormonal contraceptive choice for women with PCOS: a systematic review of randomized trials and observational studies. Gynecol Endocrinol. 2014;30:850–860.
   PubMed Web of Science ®Google Scholar
• Deplewski D, Rosenfield RL. Role of hormones in pilosebaceous unit development. Endocr Rev. 2000;21:363–392.
   PubMed Web of Science ®Google Scholar
• Azziz R, Carmina E, Dewailly D, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009;91:456–488.
   PubMed Web of Science ®Google Scholar
• Rosenfield R, Lucky A. Acne, hirsutism, and alopecia in adolescent girls. Clinical expressions of androgen excess. Endocrinol Metab Clin North Am. 1993;22:507–532.
   PubMed Web of Science ®Google Scholar
• Lucky AW, McGuire J, Rosenfield RL, et al. Plasma androgens in women with acne vulgaris. J Invest Dermatol. 1983;81:70–74.
   PubMed Web of Science ®Google Scholar
• Amiri M, Ramezani Tehrani F, Nahidi F, et al. Association between biochemical hyperandrogenism parameters and Ferriman–Gallwey score in patients with polycystic ovary syndrome: a systematic review and meta‐regression analysis. Clin Endocrinol. 2017;87:217–230.
   PubMed Web of Science ®Google Scholar
• Guzel AI, Kuyumcuoğlu U, Çelik Y. Factors affecting the degree of hirsutism in patients with polycystic ovary syndrome. Arch Gynecol Obstet. 2012;285:767–770.
   PubMed Web of Science ®Google Scholar
• Karrer-Voegeli S, Rey F, Reymond MJ, et al. Androgen dependence of hirsutism, acne, and alopecia in women: retrospective analysis of 228 patients investigated for hyperandrogenism. Medicine. 2009;88:32–45.
   PubMed Web of Science ®Google Scholar